NEW RAY MEDICINE INTL HLDG LTD

NEW RAY MEDICINE INTL HLDG LTD

0.30
HKD
+0.01
(+3.45%)
41.33MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
14.21
11.62
9.86
6.01
1.62
2.23
0.71
0.8
2.01
0.54
0.3
0.56
0.78
- -
Basic EPS, GAAP
1.28
1.67
0.58
-0.55
-0.72
0.2
-0.26
-0.42
-0.02
-0.47
-0.13
-0.19
-0.12
- -
Free Cash Flow per Basic Share
1.46
0.71
-1.03
-0.7
-0.74
0.3
-0.35
-0.19
-0.35
-0.05
-0.27
-0.03
-0.32
- -
Dividend per Share
- -
1.12
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
12.34
14.63
15.3
10.49
4.35
4.34
3.91
3.62
3.78
3.14
2.87
2.82
2.11
2.17
Tangible Book Value per Share
12.34
14.63
14.71
10.15
3.98
4.02
3.75
3.37
3.56
2.97
2.75
2.72
2.03
2.17
Basic Weighted Avg Shares
14
18
26
38
145
167
167
167
167
167
167
167
168
201
Sales/Revenue/Turnover
193
207
253
225
235
372
119
133
335
90
50
94
130
- -
Operating Margin (%)
15.3
20.79
12.14
-2.73
1.75
0.46
-18.3
-12.6
-0.71
-29.23
-31.41
-20.34
-6.46
- -
Depreciation Expense
1
1
3
4
4
4
6
6
6
6
6
3
4
- -
Net Income, GAAP
17
30
15
-20
-105
33
-44
-70
-3
-78
-22
-31
-20
- -
Effective Tax Rate (%)
39.41
32.32
50.76
- -
- -
15.29
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
9.02
14.34
5.85
-9.08
-44.64
8.92
-37.18
-52.35
-0.84
-86.83
-44.2
-33.01
-15.39
- -
Working Capital
200
273
213
210
366
362
287
316
465
396
373
301
319
315
LT Debt
- -
- -
- -
- -
- -
- -
2
1
1
- -
- -
2
2
1
Total Equity
213
303
478
472
727
725
654
606
633
526
480
471
424
436
Return on Invested Capital (%)
9.89
11.04
2.49
- -
- -
2.61
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
11.21
11.5
3.79
- -
- -
4.57
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
10.01
11.5
3.79
-4.31
-17.52
4.57
-6.39
-11.06
-0.46
-13.46
-4.41
-6.52
-4.48
- -

Capital Structure

HKD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
2
2
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
167
201
201
Market Capitalization
65
55
41

Working Capital

HKD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
319
325
344
Cash, Cash Equivalents & STI
54
37
74
Accounts Receivable, Net
59
83
92
Inventories
16
23
22
Total Current Liabilities
17
6
30
Payables & Accruals
- -
- -
- -
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

HKD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
0.25%
-6.6%
-9.92%
Free Cash Flow
112.98%
245.13%
910.62%
Net Income, GAAP
236.6%
499.45%
-35.29%
Sales/Revenue/Turnover
15.64%
32.1%
38.78%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
94
2025
- -
- -
130
2026
- -
- -
- -

Semi-annual Earnings Per Share

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.19
2025
- -
- -
-0.12
2026
- -
- -
- -

Semi-annual Dividends Per Share

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

CEO
Qiuqin Wang
Full Time Employees
31
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Dikai International Center Hangzhou Zhejiang Province China 23863
IPO Date
Oct 28, 2013
Business
New Ray Medicine International Holding Limited engages in the distribution and trading of pharmaceutical and related products and provides marketing and promotion services for drugs and chemical reagents for pharmaceutical use. The company operates through two primary segments: Distribution and trading of pharmaceutical and related products; and Provision of marketing and promotion services. It also develops, markets, and promotes a portfolio of pharmaceutical products, chemical reagents, and related healthcare services across its target markets. Headquarters are in Bermuda, and it maintains operations in the PRC (People’s Republic of China) and Hong Kong, reflecting a cross-border distribution and promotional footprint. The company was founded in 2001 and subsequently incorporated in Bermuda; its business scope includes obtaining distribution rights for pharmaceutical products, promoting and marketing activities, and offering related medical network and ancillary services as part of its broader healthcare distribution platform. Subsidiaries and partner arrangements support its regional activities and channel reach. Foundational and structural details - Founding year: 2001; Incorporation in Bermuda - Headquarters: Bermuda - Primary business activity: Distribution and trading of pharmaceutical products; marketing and promotion services for drugs and chemical reagents - Geographic footprint: PRC (including Zhejiang province), Hong Kong, and Bermuda with regional distribution networks Main products and services (core offerings) - Core pharmaceutical products: levocarnitine injections; thoymosin α1 injections; other injectable therapeutics such as cefamandole nafate, ceftizoxime sodium, and isepamicin sulfate injections used for respiratory, genitourinary, intra-abdominal, orthopedic, and septic conditions - Chemical reagents and related products: chemical reagents for pharmaceutical use; recombinant cytokine gene-derived protein injections; other pharmaceutical raw materials and reagents - Marketing and promotion services: promotional campaigns, product launch activities, physician and hospital network engagement, and related marketing support for pharmaceutical products and chemical reagents - Ancillary services: third-party medical network administration, medical and dental service provision, hospital management support, and property leasing tied to the healthcare platform Latest major company changes (within the last 1–2 years) - Strategic expansion in product portfolio: launch of a chemical reagents for pharmaceutical products in the PRC in 2024, signaling diversification beyond traditional drug distributions - Revenue and segment changes: continued growth in distribution and trading alongside expanded promotion services, with notable increases in segment revenue driven by new product launches and broader market penetration - Corporate and regulatory filings: regular reporting updates through Hong Kong stock exchange and Bermuda disclosures detailing segment performance, changes in product mix, and strategic initiatives, including improvements in distribution rights acquisitions and marketing capabilities - Ongoing partnerships and alliances: continued collaborations with pharmaceutical manufacturers and a network of distributors to broaden geographic coverage and service offerings - Operational enhancements: enhancements to the group’s marketing and promotion capabilities and regulatory compliance posture in PRC markets, aligning with expanded product lines and territories Industry context and company positioning - Industry: Pharmaceutical distribution and marketing services - Segments: Distribution and trading of pharmaceutical products; marketing and promotion services - Target markets: PRC pharmaceutical manufacturers, hospitals, and clinics; regional distributors; healthcare networks in Hong Kong and PRC - Growth trajectory: diversification into chemical reagents and allied healthcare services to complement core drug distribution; expansion of promotional services to support product launches and network development Note: Information reflects publicly disclosed materials available through corporate filings and reputable market data sources, with emphasis on the company’s stated product categories, regional operations, and recent strategic shifts.